nach oben

Erschienen in:

2016 | OriginalPaper | Buchkapitel Zur Zeit gratis

57. Antiallergische und antientzündliche Pharmakotherapie

verfasst von : A. Pautz, Juniorprof. Dr. phil. nat.

Erschienen in: Allergologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

In dem Kapitel »Antiallergische und antientzündliche Pharmakotherapie« werden die pharmakologischen Therapieoptionen zur Behandlung von den wichtigsten allergischen Erkrankungen dargestellt. Neben klassischen Medikamenten, die vorwiegend zur symptomorientierten Behandlung verwendet werden, werden neue Pharmaka, die eine zielgerichtetere Behandlung erlauben sollen, vorgestellt. Es werden die unterschiedlichen Wirkmechanismen der Medikamente sowie deren wichtigsten unerwünschten Wirkungen besprochen. Des Weiteren werden die gängigen Therapien von akuten Notfallsituationen wie des Status asthmaticus und des anaphylaktischen Schocks dargestellt.

Aktories K, Förstermann U, Hofmann FB, Starke K (2009) Allgemeine und Spezielle Pharmakologie und Toxikologie: Begründet von W. Forth, D. Henschler, W. Rummel, 10. Aufl. Elsevier, München

Alfaro V (2004) Role of histamine and platelet-activating factor in allergic rhinitis. J Physiol Biochem 60(2): 101–111

Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J Med 332(13): 868–875

Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol 163(1): 29–43

Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2013) Nationale VersorgungsLeitlinie Asthma – Kurzfassung, 2. Auflage. Version 5. 2009, zuletzt geändert: August 2013 http://www.leitlinien.de/nvl/asthma/mdb/downloads/nvl/asthma/asthma-2aufl-vers5-lang.pdf. Zugegriffen: 20.02.2015

Canonica GW, Blaiss M (2011) Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J 4(2): 47–53

Carr W, Bernstein J, Lieberman P, Meltzer E, Bachert C, Price D, Munzel U, Bousquet J (2012) A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 129(5): 1282–1289 e1210

Carr WW (2013) Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs 15(4): 303–310

Cazzola M, Page CP, Calzetta L, Matera MG (2012) Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 64(3): 450–504

Charman C, Williams H (2003) The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 21(3): 193–200

Chauhan BF, Ducharme FM (2012) Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 5: CD002314

De Luisi A, Mangialardi G, Ria R, Acuto G, Ribatti D, Vacca A (2009) Anti-angiogenic activity of carebastine: a plausible mechanism affecting airway remodelling. Eur Respir J 34(4): 958–966

Devalia JL, De Vos C, Hanotte F, Baltes E (2001) A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 56(1): 50–57

Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL (2007) Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 119(1): 176–183

de Esch IJ, Thurmond RL, Jongejan A, Leurs R (2005) The histamine H4 receptor as a new therapeutic target for inflammation. Trends Pharmacol Sci 26(9): 462–469

Feldmann RJ, Maibach HI (1967) Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol 48(2): 181–183

Fuchs M, Wetzig H, Kertscher F, Taschner R, Keller E (1999) [Iatrogenic Cushing syndrome and mutatio tarda caused by dexamethasone containing nose drops]. Hno 47(7): 647–650

Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O’Byrne PM (2011) Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 183(8): 1007–1014

Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, Hellings P, Brusselle G, De Bacquer D, van Cauwenberge P, Bachert C (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1): 110–116 e111

Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol 61(2): 391–399

Huang Z, Mancini JA (2006) Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Curr Med Chem 13(27): 3253–3262

Kamekura R, Kojima T, Takano K, Go M, Sawada N, Himi T (2012) The role of IL-33 and its receptor ST2 in human nasal epithelium with allergic rhinitis. Clin Exp Allergy 42(2): 218–228

Kempuraj D, Huang M, Kandere-Grzybowska K, Basu S, Boucher W, Letourneau R, Athanassiou A, Theoharides TC (2003) Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 132(3): 231–239

Krinner EM, Raum T, Petsch S, Bruckmaier S, Schuster I, Petersen L, Cierpka R, Abebe D, Molhoj M, Wolf A, Sorensen P, Locher M, Baeuerle PA, Hepp J (2007) A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol 44(5): 916–925

Kusters S, Schuligoi R, Huttenbrink KB, Rudert J, Wachs A, Szelenyi I, Peskar BA (2002) Effects of antihistamines on leukotriene and cytokine release from dispersed nasal polyp cells. Arzneimittelforschung 52(2): 97–102

Lambiase A, Micera A, Bonini S (2009) Multiple action agents and the eye: do they really stabilize mast cells? Curr Opin Allergy Clin Immunol 9(5): 454–465

Lee CF, Sun HL, Lu KH, Ku MS, Lue KH (2009) The comparison of cetirizine, levocetirizine and placebo for the treatment of childhood perennial allergic rhinitis. Pediatr Allergy Immunol 20(5): 493–499

Lu HR, Hermans AN, Gallacher DJ (2012) Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes? Br J Pharmacol 166(4): 1490–1502

Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, Krutmann J, Niedner R, Röcken M, Ruzicka T, Schwarz T (2009) Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. Leitlinien der Deutschen Dermatologischen Gesellschaft Nr. 013/034: 12

Lytinas M, Kempuraj D, Huang M, Kandere K, Boucher W, Letourneau R, Jeudy S, Fitzgerald K, Spear K, Athanasiou A, Theoharides TC (2002) Azelastine’s inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 23(1): 45–51

Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, Casale T (2013) Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 368(10): 924–935

McTavish D, Goa KL, Ferrill M (1990) Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy. Drugs 39(4): 552–574

Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, Garcia-Rafanell J, Forn J (1997) Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther 280(1): 114–121

Molet S, Gosset P, Lassalle P, Czarlewski W, Tonnel AB (1997) Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cells. Clin Exp Allergy 27(10): 1167–1174

Moy LY, Jia Y, Caniga M, Lieber G, Gil M, Fernandez X, Sirkowski E, Miller R, Alexander JP, Lee HH, Shin JD, Ellis JM, Chen H, Wilhelm A, Yu H, Vincent S, Chapman RW, Kelly N, Hickey E, Abraham WM, Northrup A, Miller T, Houshyar H, Crackower MA (2013) Inhibition of spleen tyrosine kinase (SYK) attenuates allergen-mediated airway constriction. Am J Respir Cell Mol Biol 49(6): 1085–1092

Mrowietz U, Czech W, Huber J, Mensing H, Ruzicka T, Schöpf E, Schopf R, Wahn U (2006) Therapie mit Ciclosporin in der Dermatologie. Leitlinien der Deutschen Dermatologischen Gesellschaft Nr. 013/013

Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SA (2012) Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367(20): 1901–1911

Noga O, Hanf G, Kunkel G, Kleine-Tebbe J (2008) Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int Arch Allergy Immunol 146(1): 66–70

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380(9842): 651–659

Pedersen S (2006) Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 29(7): 599–612

Petersen BC, Lukacs NW (2012) IL-17A and IL-25: therapeutic targets for allergic and exacerbated asthmatic disease. Future Med Chem 4(7): 833–836

Pieper MP (2012) The non-neuronal cholinergic system as novel drug target in the airways. Life Sci 91(21-22): 1113–1118

Rangno R (1997) Terfenadine therapy: can we justify the risks? Cmaj 157(1): 37–38

Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids – new mechanisms for old drugs. N Engl J Med 353(16): 1711–1723

Ring J, Beyer K, Biedermann T, Bircher A, Duda D, Fischer et al. (2014) Guideline for acute therapy und management of anaphylaxis. S2 guideline of DGAKI, AeDA, GPA, DAAU, BVKJ, ÖGAI, SGAI, DGAI, DGP, DGPM, AGATE and DAAB. Allergo J Int 23: 96–112

Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW (2001) Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev(1): CD002178

Sastre J (2008) Ebastine in allergic rhinitis and chronic idiopathic urticaria. Allergy 63 Suppl 89: 1–20

Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96(1): 23–43

Sheikh A, Ten Broek V, Brown SG, Simons FE (2007) H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 62(8): 830–837

Stahn C, Lowenberg M, Hommes DW, Buttgereit F (2007) Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 275(1-2): 71–78

Tadicherla S, Ross K, Shenefelt PD, Fenske NA (2009) Topical corticosteroids in dermatology. J Drugs Dermatol 8(12): 1093–1105

Taglialatela M, Pannaccione A, Castaldo P, Giorgio G, Annunziato L (2000) Inhibition of HERG1 K(+) channels by the novel second-generation antihistamine mizolastine. Br J Pharmacol 131(6): 1081–1088

Tasker JG, Di S, Malcher-Lopes R (2006) Minireview: rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 147(12): 5549–5556

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G (2013) Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 368(26): 2455–2466

Yanez A, Rodrigo GJ (2002) Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 89(5): 479–484

Zaidi AK, Saini SS, Macglashan DW, Jr. (2010) Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol 125(4): 902–908 e907

Titel: Antiallergische und antientzündliche Pharmakotherapie
verfasst von: A. Pautz, Juniorprof. Dr. phil. nat.
Verlag: Springer Berlin Heidelberg
Buch: Allergologie
Print ISBN: 978-3-642-37202-5

Electronic ISBN: 978-3-642-37203-2

Copyright-Jahr: 2016
DOI: https://doi.org/10.1007/978-3-642-37203-2_57

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

57. Antiallergische und antientzündliche Pharmakotherapie

Zusammenfassung

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO